PE20020082A1 - Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1) - Google Patents

Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)

Info

Publication number: PE20020082A1
Authority: PE; Peru
Prior art keywords: angiotensin; pharmaceutical composition; composition including; synthase inhibitor; receptor antagonist
Prior art date: 2000-04-12

Application number

PE2001000328A

Other languages

English (en)

Spanish (es)

Inventor

Ronald Edward Steele

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2001-04-10

Publication date

2002-02-21

2001-04-10 Application filed by Novartis Ag filed Critical Novartis Ag

2002-02-21 Publication of PE20020082A1 publication Critical patent/PE20020082A1/es

Links

229940123338 Aldosterone synthase inhibitor Drugs 0.000 title abstract 2
239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
229940126317 angiotensin II receptor antagonist Drugs 0.000 title 1
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
229960000932 candesartan Drugs 0.000 abstract 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
229960004563 eprosartan Drugs 0.000 abstract 1
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
229960000255 exemestane Drugs 0.000 abstract 1
229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
229960002198 irbesartan Drugs 0.000 abstract 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
229960004773 losartan Drugs 0.000 abstract 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
229960004699 valsartan Drugs 0.000 abstract 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE2001000328A 2000-04-12 2001-04-10 Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1) PE20020082A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19674200P	2000-04-12	2000-04-12

Publications (1)

Publication Number	Publication Date
PE20020082A1 true PE20020082A1 (es)	2002-02-21

Family

ID=22726655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2001000328A PE20020082A1 (es)	2000-04-12	2001-04-10	Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)

Country Status (19)

Country	Link
EP (1)	EP1282410A2 (fr)
JP (1)	JP2003530343A (fr)
KR (1)	KR20020089437A (fr)
CN (1)	CN1422152A (fr)
AR (1)	AR032316A1 (fr)
AU (2)	AU2001273938B2 (fr)
BR (1)	BR0110079A (fr)
CA (1)	CA2405895A1 (fr)
HU (1)	HUP0301335A3 (fr)
IL (1)	IL152081A0 (fr)
MX (1)	MXPA02010091A (fr)
NO (1)	NO20024920L (fr)
NZ (1)	NZ521855A (fr)
PE (1)	PE20020082A1 (fr)
PL (1)	PL358459A1 (fr)
RU (1)	RU2002129569A (fr)
SK (1)	SK14612002A3 (fr)
WO (1)	WO2001076574A2 (fr)
ZA (1)	ZA200208204B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030162759A1 (en) *	2000-07-27	2003-08-28	Ricardo Rocha	Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6777443B2 (en)	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives
US7232828B2 (en) *	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004060399A1 (fr) *	2002-12-27	2004-07-22	Takeda Pharmaceutical Company Limited	Inhibiteur de prise de poids corporel
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
WO2005099695A1 (fr) *	2004-04-19	2005-10-27	Novartis Ag	Systemes d'administration de medicament destine a la prevention et au traitement de maladies vasculaires
ITTO20040760A1 (it) *	2004-11-03	2005-02-03	Uni Degli Studi Del Piemonte	Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare
US20080102120A1 (en) *	2004-12-24	2008-05-01	Miha Vrbinc	Solid Pharmaceutical Composition Comprising Valsartan
EP1674080A1 (fr) *	2004-12-24	2006-06-28	KRKA, D.D., Novo Mesto	Composition pharmaceutique comprenant du valsartan
EP1853261B1 (fr)	2005-03-03	2017-01-11	Universität des Saarlandes	Inhibiteurs selectifs de synthases de corticoides humaines
TW200716636A (en) *	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
EP1842543A1 (fr)	2006-04-05	2007-10-10	Speedel Pharma AG	Composition pharmaceutique comprennant un inhibiteur de l'aldosteron synthase et un antagoniste de recepteur mineralcorticoide
TW200808812A (en) *	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
TW200808813A (en)	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
EP2095819A1 (fr) *	2008-02-28	2009-09-02	Maastricht University	Dérivés de N-benzyle imidazole et leur utilisation comme inhibiteurs de l'aldosterone synthase
EA201101672A1 (ru)	2009-05-28	2012-06-29	Новартис Аг	Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
RS53664B1 (en)	2009-05-28	2015-04-30	Novartis Ag	SUBSTITUTED AMINOPROPIONIC ACID DERIVATIVES AS NEPRILIZINE INHIBITORS
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
KR20140056258A (ko)	2011-07-08	2014-05-09	노파르티스 아게	높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP2956464B1 (fr)	2013-02-14	2018-03-28	Novartis AG	Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
TW201518323A (zh)	2013-07-25	2015-05-16	Novartis Ag	合成ａｐｅｌｉｎ多肽之生物結合物
EA201690278A1 (ru)	2013-07-25	2016-06-30	Новартис Аг	Циклические полипептиды для лечения сердечной недостаточности
SG11201704758XA (en)	2015-01-23	2017-08-30	Novartis Ag	Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
AU2017350484B2 (en) *	2016-10-27	2021-12-02	Damian Pharma Ag	Aldosterone synthase inhibitor
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
SG11202010906XA (en)	2018-05-03	2020-12-30	Damian Pharma Ag	R-fadrozole for use in the treatment of aldostonerism
EP3887388A1 (fr)	2018-11-27	2021-10-06	Novartis AG	Peptides cycliques servant d'inhibiteurs de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) pour le traitement de troubles métaboliques
UY38485A (es)	2018-11-27	2020-06-30	Novartis Ag	Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
CN113166101A (zh)	2018-11-27	2021-07-23	诺华股份有限公司	作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
TW202333563A (zh)	2021-11-12	2023-09-01	瑞士商諾華公司	用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2024241229A1 (fr)	2023-05-24	2024-11-28	Novartis Ag	Dérivés de naphtyridinone pour le traitement d'une maladie ou d'un trouble

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5252565A (en) *	1990-04-02	1993-10-12	Merrell Dow Pharmaceuticals Inc.	Haloethyl-substituted steroid enzyme inhibitors
JPH0971586A (ja) *	1995-09-07	1997-03-18	Yamanouchi Pharmaceut Co Ltd	新規な二環性縮合イミダゾール誘導体
DK0930876T3 (da) *	1996-07-22	2005-02-14	Renovo Ltd	Anvendelse af forbindelser, der fremmer estrogen aktivitet, til behandling af sår
US5906987A (en) *	1997-03-10	1999-05-25	Schering Aktiengesellschaft And Board Of Regents	Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
FR2766821A1 (fr) *	1997-07-29	1999-02-05	Sanofi Sa	Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese
US5972921A (en) *	1997-12-12	1999-10-26	Hormos Medical Oy Ltd.	Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ZA991922B (en) *	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
DE122007000055I1 (de) *	1998-07-10	2007-12-13	Novartis Pharma Ag	Bluthochdruckgegenmittel-Kombination des valsartanund kalziumkanal Blocker

2001
- 2001-04-10 CA CA002405895A patent/CA2405895A1/fr not_active Abandoned
- 2001-04-10 IL IL15208101A patent/IL152081A0/xx unknown
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/es not_active Application Discontinuation
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/pt not_active IP Right Cessation
- 2001-04-10 PL PL01358459A patent/PL358459A1/xx not_active Application Discontinuation
- 2001-04-10 AR ARP010101698A patent/AR032316A1/es not_active Application Discontinuation
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/ja active Pending
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 EP EP01940317A patent/EP1282410A2/fr not_active Withdrawn
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/hu unknown
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/sk unknown
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/es not_active Application Discontinuation
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/ru not_active Application Discontinuation
- 2001-04-10 CN CN01807917A patent/CN1422152A/zh active Pending
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/fr not_active Application Discontinuation
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 AU AU7393801A patent/AU7393801A/xx active Pending
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/ko not_active Ceased
2002
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown
- 2002-10-11 NO NO20024920A patent/NO20024920L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SK14612002A3 (sk)	2003-05-02
AR032316A1 (es)	2003-11-05
CA2405895A1 (fr)	2001-10-18
NO20024920L (no)	2002-11-27
ZA200208204B (en)	2003-10-14
AU2001273938B2 (en)	2005-03-03
EP1282410A2 (fr)	2003-02-12
IL152081A0 (en)	2003-05-29
JP2003530343A (ja)	2003-10-14
NO20024920D0 (no)	2002-10-11
MXPA02010091A (es)	2003-02-12
AU7393801A (en)	2001-10-23
NZ521855A (en)	2004-10-29
KR20020089437A (ko)	2002-11-29
HUP0301335A3 (en)	2006-02-28
BR0110079A (pt)	2002-12-31
PL358459A1 (en)	2004-08-09
WO2001076574A3 (fr)	2002-04-25
WO2001076574A2 (fr)	2001-10-18
HUP0301335A2 (hu)	2003-08-28
CN1422152A (zh)	2003-06-04
RU2002129569A (ru)	2004-03-27

Legal Events

Date	Code	Title	Description
2005-07-27	FC	Refusal

Publication	Publication Date	Title
PE20020082A1 (es)	2002-02-21	Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
PE20070803A1 (es)	2007-09-10	Combinacion farmaceutica de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra
PE107099A1 (es)	1999-11-06	Composicion de atorvastatina y un antihipertensor
CR7548A (es)	2006-12-01	Derivados de triazole como antagonistas del receptor de tachykinin
PE20120315A1 (es)	2012-04-07	Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino
CL2009000394A1 (es)	2011-02-11	Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
WO2005011646A3 (fr)	2005-04-21	Derives de bloqueur du recepteur de l'angiotensine ii
PE20081557A1 (es)	2008-10-30	Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
MX2009005358A (es)	2009-06-05	Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
CL2003002731A1 (es)	2005-01-07	Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
CL2010001361A1 (es)	2011-07-29	Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
NO20063380L (no)	2006-09-22	Triazolderivater som vasopressinantagonister
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
GT200900328A (es)	2011-08-29	Derivados de bencimidazol
PE20061195A1 (es)	2006-12-21	Derivado de bencimidazol como antagonista de angiotensina ii
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
TW200744593A (en)	2007-12-16	Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
WO2008123207A1 (fr)	2008-10-16	Dérivé de l'ornithine
DOP2010000075A (es)	2010-07-15	Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo
PL1843754T3 (pl)	2011-12-30	Nowa kompozycja farmaceutyczna zawierająca cyleksetyl kandesartanu jako lipofilową substancję krystaliczną
WO2006110884A8 (fr)	2006-12-14	Pyrimidines substituees utilisees comme antagonistes du recepteur d'adenosine
WO2008116185A3 (fr)	2009-03-12	Pyrimidines substituées utilisées comme antagonistes des récepteurs de l'adénosine
RU2006117790A (ru)	2007-12-10	Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением
EA200901295A1 (ru)	2010-04-30	Кристаллический 1-(циклогексилоксикарбонилокси)этил-1-((2`-цианодифенил-4-ил)метил)-2-этокси-1н-бензо[d]имидазол-7-карбоксилат и способ его получения
MY144635A (en)	2011-10-14	2-oxo-1,2,4,5-tetrahydro-1,-3-benzodiazepin-3-yl-piperidines used as cgrp antagonists